<div id="readability-page-1"><p>Investment analysts at StockNews.com assumed coverage on shares of <span>bluebird bio (NASDAQ:BLUE - Get Free Report)</span> in a research note issued to investors on Monday. The brokerage set a &#34;sell&#34; rating on the biotechnology company's stock.</p><ul><li>Beam Therapeutics Bolts Higher on Gene Therapy Licensing Payments</li></ul><p>Several other research analysts also recently weighed in on BLUE. Barclays cut their target price on shares of bluebird bio from $4.00 to $2.00 and set an &#34;overweight&#34; rating for the company in a research note on Friday. Robert W. Baird cut their price objective on bluebird bio from $7.00 to $6.00 and set an &#34;outperform&#34; rating on the stock in a research report on Thursday, August 15th. Bank of America downgraded shares of bluebird bio from a &#34;buy&#34; rating to a &#34;neutral&#34; rating and decreased their target price for the company from $3.00 to $0.50 in a research note on Friday. Cantor Fitzgerald  restated a &#34;neutral&#34; rating on shares of bluebird bio in a report on Monday, September 16th. Finally, JPMorgan Chase &amp; Co. cut shares of bluebird bio from a &#34;neutral&#34; rating to an &#34;underweight&#34; rating in a research report on Friday. Three equities research analysts have rated the stock with a sell rating, seven have given a hold rating and two have issued  a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of &#34;Hold&#34; and an average price target of $3.03.</p><p><b>View Our Latest Analysis on bluebird bio</b></p><h2>bluebird bio Trading Down 11.5 %</h2><ul><li>MarketBeat Week in Review – 2/26 - 3/1</li></ul><p>Shares of BLUE stock opened at $0.32 on Monday. The stock has a market cap of $62.21 million, a P/E ratio of -0.17 and a beta of 0.76. The company has a quick ratio of 0.57, a current ratio of 0.68 and a debt-to-equity ratio of 0.37. bluebird bio has a fifty-two week low of $0.32 and a fifty-two week high of $5.53. The business has a fifty day simple moving average of $0.49 and a 200-day simple moving average of $0.78. </p><p>bluebird bio (NASDAQ:BLUE - Get Free Report) last posted its earnings results on Friday, September 13th. The biotechnology company reported ($0.36) earnings per share for the quarter. The business had revenue of $18.57 million for the quarter. bluebird bio had a negative net margin of 565.74% and a negative return on equity of 238.15%.  On average, analysts forecast that  bluebird bio will post -1.41 earnings per share for the current fiscal year. </p><h2>Institutional Inflows and Outflows</h2><ul><li>bluebird bio Stock Signals Potential to be a Multi-bagger </li></ul><p>A number of institutional investors have recently made changes to their positions in BLUE. Allegheny Financial Group LTD bought a new position in  bluebird bio during the second quarter worth $25,000.  Verition Fund Management LLC acquired a new stake in shares of  bluebird bio during the 3rd quarter worth about $42,000.  Bayesian Capital Management LP bought a new position in  bluebird bio during the 1st quarter valued at about $52,000.  SG Americas Securities LLC boosted its stake in  bluebird bio by 152.4% in the third quarter. SG Americas Securities LLC now owns 122,855 shares of the biotechnology company's stock worth $64,000 after purchasing an additional 74,185 shares in the last quarter.  Finally, Price T Rowe Associates Inc. MD lifted its position in shares of  bluebird bio by 113.7% during the first quarter. Price T Rowe Associates Inc. MD now owns 54,714 shares of the biotechnology company's stock worth $71,000 after purchasing an additional 29,113 shares in the last quarter. 87.43% of the stock is owned by institutional investors. </p><h2>bluebird bio Company Profile</h2> (Get Free Report)<p>bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.</p><h2>See Also</h2><ul><li>Five stocks we like better than bluebird bio</li><li>EV Stocks and How to Profit from Them </li><li>Warren Buffett, Cathie Wood Own Nu Holdings, Should You? </li><li>Are Penny Stocks a Good Fit for Your Portfolio?</li><li>MercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?</li><li>What is the Nasdaq? Complete Overview with History</li><li>ORIC: Working with Two Pharma Giants, Analysts See +100% Upside</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QkxVRQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="330" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QkxVRQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><p>→ ❗ RSVP please! <span><span>(From Behind the Markets)</span> <span>(Ad)</span></span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMDU0Mw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMDU0Mw"/></p><h2>Should you invest $1,000 in bluebird bio right now?</h2><p>Before you consider bluebird bio, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and bluebird bio wasn't on the list.</p><p>While bluebird bio currently has a &#34;Hold&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

BLUE

<p>StockNews.com has initiated coverage on bluebird bio (NASDAQ:BLUE), assigning a "sell" rating. Other analysts have also adjusted their ratings, with Barclays setting an "overweight" rating, while Bank of America downgraded it to "neutral". Currently, the stock has a consensus rating of "Hold" with an average price target of $3.03. bluebird bio reported a negative net margin of 565.74% and is expected to post -$1.41 earnings per share for the fiscal year. Institutional investors hold 87.43% of the stock.</p>

bluebird bio (NASDAQ:BLUE) Now Covered by StockNews.com